AbbVie Inc (ABBV)
164.99
-4.64
(-2.74%)
USD |
NYSE |
Nov 15, 16:00
165.15
+0.16
(+0.10%)
Pre-Market: 20:00
AbbVie Research and Development Expense (TTM): 8.722B for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 8.722B |
| June 30, 2024 | 8.315B |
| March 31, 2024 | 8.10B |
| December 31, 2023 | 8.453B |
| September 30, 2023 | 7.781B |
| June 30, 2023 | 7.712B |
| March 31, 2023 | 7.857B |
| December 31, 2022 | 7.207B |
| September 30, 2022 | 7.406B |
| June 30, 2022 | 7.815B |
| March 31, 2022 | 7.836B |
| December 31, 2021 | 8.046B |
| September 30, 2021 | 8.004B |
| June 30, 2021 | 7.692B |
| March 31, 2021 | 8.228B |
| December 31, 2020 | 7.755B |
| September 30, 2020 | 7.246B |
| June 30, 2020 | 7.78B |
| March 31, 2020 | 6.727B |
| December 31, 2019 | 6.792B |
| September 30, 2019 | 11.91B |
| June 30, 2019 | 10.94B |
| March 31, 2019 | 10.88B |
| December 31, 2018 | 10.75B |
| September 30, 2018 | 5.678B |
| Date | Value |
|---|---|
| June 30, 2018 | 5.583B |
| March 31, 2018 | 5.505B |
| December 31, 2017 | 5.334B |
| September 30, 2017 | 4.863B |
| June 30, 2017 | 4.821B |
| March 31, 2017 | 4.771B |
| December 31, 2016 | 4.585B |
| September 30, 2016 | 4.411B |
| June 30, 2016 | 4.643B |
| March 31, 2016 | 4.453B |
| December 31, 2015 | 4.435B |
| September 30, 2015 | 4.267B |
| June 30, 2015 | 3.969B |
| March 31, 2015 | 3.815B |
| December 31, 2014 | 3.649B |
| September 30, 2014 | 3.588B |
| June 30, 2014 | 3.402B |
| March 31, 2014 | 3.331B |
| December 31, 2013 | 3.193B |
| September 30, 2013 | 3.056B |
| June 30, 2013 | 2.935B |
| March 31, 2013 | 2.908B |
| December 31, 2012 | 3.066B |
| September 30, 2012 | 3.806B |
| June 30, 2012 | 3.658B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
6.727B
Minimum
Mar 2020
8.722B
Maximum
Sep 2024
7.774B
Average
7.798B
Median
Research and Development Expense (TTM) Benchmarks
| Amgen Inc | 5.774B |
| Johnson & Johnson | 16.41B |
| Eli Lilly and Co | 10.53B |
| Merck & Co Inc | 22.98B |
| Pfizer Inc | 10.60B |